日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Use of CD19-targeted immune modulation to eradicate AAV-neutralizing antibodies.

利用 CD19 靶向免疫调节来根除 AAV 中和抗体

Doshi Bhavya S, Markmann Caroline A, Novak Noelle, Juarez Rojas Silvia, Davidson Robert, Chau Julia Q, Wang Wei, Carrig Sean, Martos Rus Cristina, Samelson-Jones Benjamin J, Small Juliana C, Bhoj Vijay G, George Lindsey A

TRPML1 activation ameliorates lysosomal phenotypes in CLN3 deficient retinal pigment epithelial cells

TRPML1 激活可改善 CLN3 缺陷型视网膜色素上皮细胞的溶酶体表型

D Wünkhaus, R Tang, K Nyame, N N Laqtom, M Schweizer, A Scotto Rosato, E K Krogsæter, C Wollnik, M Abu-Remaileh, C Grimm, G Hermey, R Kuhn, D Gruber-Schoffnegger, S Markmann

Defining outcomes for beta cell replacement therapy: a work in progress

定义β细胞替代疗法的疗效指标:一项正在进行的工作

Piemonti, Lorenzo; de Koning, Eelco J P; Berney, Thierry; Odorico, Jon S; Markmann, James F; Stock, Peter G; Rickels, Michael R

Anti-CD45RB/anti-TIM-1-induced tolerance requires regulatory B cells

抗CD45RB/抗TIM-1诱导的耐受性需要调节性B细胞

Lee, K M; Kim, J I; Stott, R; Soohoo, J; O'Connor, M R; Yeh, H; Zhao, G; Eliades, P; Fox, C; Cheng, N; Deng, S; Markmann, J F